Trial Profile

A Phase 1 Trial of Sleeping Beauty-Modified Third-Generation Anti-CD19 CAR T-Cell Therapy (TCRs) to Treat Solid Tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 chimeric antigen receptor T cell therapy Alaunos Therapeutics (Primary)
Indications Solid tumours
Focus Adverse reactions

08 Aug 2019 According to a ZIOPHARM Oncology media release, this trial is expected to begin in late 2019.
05 Mar 2019 According to a ZIOPHARM Oncology media release, The Company affirms guidance on beginning this trial and treating patients at MD Anderson Cancer Center in the second half of this year.
09 Oct 2018 According to a ZIOPHARM Oncology media release, the company have affirmed its guidance on this planned phase I study.The IND application for this phase 1 trial remains on track to be submitted in the fourth quarter of 2018 followed by enrollment of patients beginning in 2019, pending regulatory clearance.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com